Immunotherapy / IL-2 agonistPhase 3 trialInvestigational

Bempegaldesleukin

How it works

Stimulates the production of IL-2, a protein that helps activate immune cells to attack cancer cells.

Cancer types

Melanoma— All patients

Efficacy

In clinical trials, bempegaldesleukin improved response rates in patients with advanced melanoma, with a response rate of approximately 44%.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

Evidence from research

Study	Cancer type	Stage	Efficacy
New Study Compares Melanoma Treatment with Two Immunotherapy Drugs	Melanoma	phase-3	—	Source →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.